Back to results
US 7,608,414 B2Granted
Method for diagnosing and prognosing inflammatory bowel disease and crohn's disease
AssigneeGlycominds Ltd.
InventorsNir Dotan, Avinoam Dukler, Rom T. Altstock
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for diagnosing and prognosing Inflammatory Bowel disease or Crohn's disease (CD) by measuring levels of antibodies to glycans in a biological sample.
Claims10
A method for distinguishing between complicated and non-complicated Crohn's disease in a subject, the method comprising,
- providing a test sample from a subject diagnosed with Crohn's disease;
- detecting a level of an anti-Glc(β1,3)Glc(β) antibody (ALCA) in said sample by binding of said ALCA in said sample to a carbohydrate reagent comprising an isolated Glc(β1,3)Glc(β) glycan;
- detecting a level of an anti-GlcNAc(β1,4)GlcNAc(β) antibody (ACCA) in said sample by binding of said ACCA in said sample to a carbohydrate reagent comprising an isolated GlcNAc(β1,4)GIcNAc(β) glycan;
- detecting a level of an anti-mannan antibody (ASCA) in said sample by binding of said ASCA in said sample to a carbohydrate reagent comprising an isolated mannan;
- detecting a level of an anti-Man(α1,3)Man(α) antibody (AMCA) in said sample by binding of said AMCA in said sample to a carbohydrate reagent comprising an isolated Man(α1,3)Man(α);
- and
- distinguishing a complicated disease course in said subject by detection of an elevated level of each of said ALCA, ACCA, ASCA, and AMCA in said test sample relative to a control reference sample from one or more individuals known to have non-complicated Crohn's disease.
4 more elements
The method of 9, wherein said anti-Glc(β1,3)Glc(β) antibody (ALCA) is an IgG antibody and said anti-GlcNAc(β1,4)GlcNAc(β) antibody (ACCA) is an IgA antibody.
Dependencies are inferred from the claim text.